An observational study in Lymphoproliferative Disorders, Premalignant and Monoclonal B-Cell Lymphocytosis, sponsored by University of Haifa. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by University of Haifa · Observational
This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 146 across 215 observational studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →University of Haifa is the lead sponsor of 105 studies on the registry; 27 are open to participants now.
Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoproliferative Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Jewish and Arab LPD families with at least 2 family members with LPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have LPD and must have a family history of LPD. LPD patients who signed an to participate in the study.
Criteria for the inclusion of relatives of patients:
Relatives must be related by blood to LPD patients or unrelated (for control group).
Relatives who signed an informed consent to participate in the study.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bnai Zion Medical Center
Other: No intervention
Tel Aviv Sourasky Medical Center - Ichilov Hospital
Other: No intervention
Galil Medical Center
Other: No intervention
Ziv Medical Center
Other: No intervention
Emek Medical Center
Other: No intervention
Beilinson Hospital
Other: No intervention
Meir Medical Center
Other: No intervention
Kaplan Medical Center
Other: No intervention
Sheba Medical Center
Other: No intervention
Rambam Medical Center
Other: No intervention
Shaare Zdek Medical Center
Other: No intervention
Hadassah Medical Center
Other: No intervention
Shamir Medical Center (Assaf Harofeh)
Other: No intervention
Soroka Medical Center
Other: No intervention
Assuta Ashdod Hospital
Other: No intervention
No intervention
Prevalence of familial LPD in Israel
Time frame: 5 years
Association between medical history and genetic variants and the risk of familial LPD
Time frame: 5 years
Risk of clinical outcomes among familial LPD and family members
Time frame: 15 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for Dec 2028, 54 months later.
Of 70 non-industry observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 30. This study's planned 54 months is below that.
Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 32 and three quarters within 176.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Lymphocytic, Chronic, B-Cell →